03 June 2026
03 June 2026
The study marks the first-in-human trial of MOON101 and plans to enrol up to 40 participants at various clinical sites across the US.
A decision from the FDA is anticipated by 30 November 2026.
With the clearance, Philips brings workflow automation and image quality features to ultrasound, aiming to standardise routine examinations.
Key findings show mean IgA reductions of around 70% from baseline, sustained at 12 weeks at the 700mg dose.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
